Paulson & Co’s Immunogen Inc IMGN Stock Holding History

Paulson & Co’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-229,222	Closed	-$1.63M	–	93
2017 Q2	$1.63M	Buy	+229,222	New	+$1.05M	0.02%	96

Other funds holding IMGN

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Paulson & Co's IMGN Position: Q3 2017 in Review

Paulson & Co sold out of Immunogen Inc (IMGN) in Q3 2017, closing a stake of 229,222 shares — an estimated $1.63M sold.

Paulson & Co first reported a position in IMGN in Q2 2017 and held it in 1 quarter. The position peaked at $1.63M in Q2 2017. 180 funds tracked by Wall St. Rank hold IMGN as of Q3 2017.

Paulson & Co reported no remaining Immunogen Inc position as of Q3 2017 after selling out during the quarter.
Paulson & Co sold 229,222 Immunogen Inc shares in Q3 2017, an estimated $1.63M.
Paulson & Co first reported a position in Immunogen Inc in Q2 2017 and held it in 1 quarter.
Paulson & Co's Immunogen Inc position peaked at $1.63M in Q2 2017.
180 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.